RxDoctor Payments Data

Breanna Ramsey, APRN

Family · Pikeville, KYNPI 1881478105

Payments from drug & device makers

$2,362in general payments, 2019–2025

Across 83 payments — averaging $28.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$306
  • Boehringer Ingelheim$178
  • Novartis$176
  • Boston Scientific$96
  • United Therapeutics Corporation$96
  • plus $242 from 8 others

What the payments were for

  • Travel & lodging$1,14949%
  • Food & beverage$1,21351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,362 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,875
Medicare patients
194
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$185,758
EntrestoSacubitril/Valsartan137$118,616
JardianceEmpagliflozin58$54,458
FarxigaDapagliflozin Propanediol49$45,083
XareltoRivaroxaban49$43,437
BrilintaTicagrelor16$15,504
Ranolazine ErRanolazine68$4,117
Metoprolol Succinate277$2,135
Potassium Chloride136$1,667
Bumetanide39$1,558
Atorvastatin Calcium226$1,317
Amiodarone Hcl84$1,201
ClopidogrelClopidogrel Bisulfate139$862
Omega-3 Acid Ethyl Esters29$660
Nitroglycerin40$659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$185,758217 claims
NovartisEntresto$176$118,616137 claims
AstraZenecaFarxiga, Brilinta$37$60,58765 claims
Boehringer IngelheimJardiance$178$54,45858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →